Jian Chen
Director - Translational Research & Preclinical Development BioAtla
Dr. Jian Chen is a translational R&D leader with over 20 years of experience in biologics and ADC development, currently serving as Director of Translational Research at BioAtla. He has led preclinical programs and IND clearances for multiple CAB-ADCs, including BA3361, and directs biomarker strategies from discovery through clinical trials. His recent work includes developing novel senolytic ADCs and presenting biomarker strategies for patient selection. Formerly a faculty member at MD Anderson for 14 years, he brings deep expertise in oncology and the tumor microenvironment to advance next-generation ADC therapeutics.
Seminars
- Highlighting the benefits and potential of conditionally activated ADCs against traditional conjugate design
- Exploring Conditionally Active Biologic mechanism leveraging tumor pH and physiological conditions for ADC activation
- Spotlighting PD profiles of conditionally active ADCs to demonstrate improved therapeutic index
With more ADCs entering the clinic than ever before, it has never been more important to optimize clinical strategies to demonstrate differentiation and benefit oncology patients.
Attend this session to follow ADC clinical trends across development phases from early to late-stage, and contextualize evolving strategies to stand out from the crowd and maximize differentiation opportunity in crowded oncology indications.
Workshop highlights include:
- Breaking down the ADC clinical development trends in an increasingly busy oncology treatment landscape: How will ADCs fit into future patient therapy regiments?
- Evolving strategies to unlock clinical benefit across combination and sequencing approaches as more ADCs are approved, particularly into front-line patient therapies
- Finding the right patient for the right ADC: Evaluating when and how to implement patient cut-off criteria
